Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease

Relapsing Remitting Multiple Sclerosis Clinical Trial

— OVERLORD-MS  

Official title:

Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04578639
• Other study ID #: 2020-001205-23
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: November 2, 2020
• Est. completion date: May 14, 2025

Study information

• Verified date: August 2023
• Source: Haukeland University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter non-inferiority study, designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years.

Description:

The objective of the study is to demonstrate if rituximab is non-inferior to ocrelizumab with regards to efficacy and safety in treatment naïve RRMS patients, diagnosed within the last 12 months. To test this hypothesis, the investigators aim to perform a 30-months (24 + 6 months) prospective randomized double blinded multicenter non-inferiority study to compare rituximab to ocrelizumab in RRMS. MS disease activity as measured by brain MRI is more sensitive as compared to clinical disease activity as measured by number of relapses or disability progression. New or enlarging MRI T2 lesions is regarded an acceptable marker of disease activity, and is routinely used in clinical practice by annual examinations (Thompson, Baranzini et al. 2018) (Thompson, Banwell et al. 2018). The investigators will therefore use the proportion of patients with no new or enlarging T2-weighted brain MRI lesions from month 6 to month 24 as the primary endpoint of this study. Secondary objectives are included to further evaluate potential the difference or similarities in effectiveness between the treatments (disability progression, relapse rate, T25FW, 9-HPT, SDMT), to evaluate the difference in safety issues (most notably hematological complications, infections, malignancies, infusion reactions and other serious adverse events) and to evaluate the difference in patient reported outcomes by evaluation of working status, fatigue, anxiety and depressive symptoms, quality of life and treatment satisfaction (EQ-5D, MSIS-29, FSMC, and SDMT). The exploratory outcomes are included to evaluate specific blood samples and plasma biomarkers for treatment response (sNFL and CD19+ cell counts) and side effects (hypogammaglobulinemia and neutropenia) of the two treatments, differences in vaccination status (pneumococcus and/or influenza) and to determine the predictive value of BICAMS for the individual patient.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 214
• Est. completion date: May 14, 2025
• Est. primary completion date: May 14, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Male and female patients, treatment naïve, and aged between 18 and 60 years included

2. Women of childbearing potential1 (WOCBP) able and willing to use highly effective methods of birth control2 per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly for the duration of the study OR until 3 months after last dose administered.

3. A diagnosis of RRMS according to the 2017 revised diagnostic criteria of McDonald (Thompson, Banwell et al. 2018) within the last 12 months.

4. Disease activity defined as = 1 relapse3 or = 1 new MRI lesion during the last 12 months

5. EDSS score = 4.0

6. Absence of comorbidity or drug abuse that preclude study participation

7. Able to complete treatment or follow-up visits in the study (e.g. no contraindications for MRI or plans of moving)

8. Able to understand written and spoken Norwegian or English

9. Capable of giving signed informed consent as described in Appendix 1.2 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

1. Known hypersensitivity or other known side effects for any of the study medications, including co-medications such as high glucocorticosteroids

2. A diagnosis of primary progressive MS according to the revised diagnostic criteria of McDonald (Thompson, Banwell et al. 2018)

3. A disease course of secondary progressive MS (Lublin, Reingold et al. 2014)

4. Any ongoing infection, including tuberculosis, hepatitis virus or HIV, as well as hepatitis B surface antigen positivity and/or hepatitis C PCR positivity verified at screening visit.

5. Prior or current psychiatric illness, mental deficiency or cognitive dysfunction influencing the patient ability to make an informed consent or comply with the treatment and follow-up phases of this protocol.

6. Cardiac insufficiency, cardiomyopathy, significant cardiac dysrhythmia, unstable or advanced ischemic heart disease (NYHA III or IV)

7. Active malignancy or prior history of malignancy except localized basal cell, squamous skin cancer or carcinoma in situ of the cervix.

8. WBC < 1.5 x 109/L if not caused by a reversible effect of documented ongoing medication. If WBC < 1.5 x 109/L is caused by a reversible effect of documented ongoing medication the WBC count must be > 1,5 x 109/L before start of study treatment.

9. Platelet (thrombocyte) count < 100 x 109/L

10. ALAT and/or ASAT more than 2 times the upper normal reference limit (ULN)

11. Serum creatinine > 200 µmol/L

12. Serum bilirubin > ULN

13. Pregnancy or lactating female patients

14. Any disease that can influence the patient safety and compliance, or the evaluation of disability

15. History of serious or life-threatening infusion reaction to ocrelizumab or rituximab, if previously treated with these medications for other diseases than MS

16. Previous use of MS-therapies such as natalizumab, fingolimod, interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, cladribine, rituximab, alemtuzumab, ocrelizumab, hematopoietic stem cell therapy (HSCT) or other immunosuppression therapies with long lasting effects, or any other disease modifying therapy (DMT) for MS. If any of these medications have been used against other diseases than MS, patients can be included if the medications have not been used the previous year before enrollment.

17. Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study (s), or receiving other investigational treatment(s). Patients participating in a purely observational trial will not be excluded.

18. Presence of metallic objects implanted in the body, or allergy to MRI contrast that would preclude the ability of the patient to safely have MRI exams

19. Current alcohol or drug dependencies

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Relapsing-Remitting
• Relapsing Remitting Multiple Sclerosis

Intervention

Drug:
• Rituximab
A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
• Ocrelizumab
A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.

Locations

Country	Name	City	State
Norway	Haukeland University Hospital	Bergen
Norway	Nordlandsykehuset HF	Bodø
Norway	Vestre Viken syekhus	Drammen
Norway	Sørlandet Sykehus	Kristiansand
Norway	Molde sjukehus	Molde
Norway	Sykehuset Namsos	Namsos
Norway	Akershus University Hospital	Oslo
Norway	Oslo University Hospital	Oslo
Norway	Oslo University Hospital HF	Oslo
Norway	Sykehuset Telemark	Skien
Norway	Stavanger University Hospital HF	Stavanger
Norway	University Hospital North Norway	Tromsø
Norway	University Hospital North Norway HF	Tromsø
Norway	St. Olavs Hospital	Trondheim
Sweden	Karolinska Hospital	Stockholm

Sponsors (6)

Lead Sponsor	Collaborator
Haukeland University Hospital	Helse Stavanger HF, Oslo University Hospital, St. Olavs Hospital, University Hospital of North Norway, University Hospital, Akershus

Countries where clinical trial is conducted

Norway,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Proportion of patients with hypogammaglobinemia	The proportion of patients with hypogammaglobinemia during 24 months of treatment	From baseline to month 24
Other	The proportion of patients with neutropenia	The proportion of patients with neutropenia during 24 months of treatment	From baseline to month 24
Other	Level and duration of B cell depletion	The level and duration of B cell depletion during 24 months of treatment	From baseline to month 24
Other	Level of CD27+ depletion	The level of CD27+ B memory cell depletion during 24 months of treatment	From baseline to month 24
Other	Change in serum levels of neurofilament (Nfl)	Change in serum levels of neurofilament (Nfl) during 24 months of treatment	From baseline to month 24
Other	Influence of different FcR genotypes	The influence of different FcR genotypes on B-cell depletion during 24 months of treatment	From baseline to month 24
Other	Influence of serum levels of vitamin D	The influence of serum levels of vitamin D on efficacy during 24 months of treatment	From baseline to month 24
Other	Change in cognition as measured by BICAMS	The BICAMS is a brief cognitive assessment that can be used also in study sites with staff members with no neuropsychological training (Walker, Osman et al. 2016) The tests address specific cognitive deficits that are common in MS patients, and the scales were chosen also for their psychometric qualities (reliability, validity and sensitivity) (Langdon, Amato et al. 2012). Tests must be administered during daytime, in a standardized manner, and in a quiet room. The order of tests will be fixed: the Symbol Digit Modalities Test (SDMT), Brief Visuospatial Memory Test-Revised (BVMT-R), and California Verbal Learning Test-II (CVLT-II). BICAMS has been validated for use in Norwegian MS-patients	From baseline to month 24
Other	Vaccination response	Vaccination response as measured by specific pneumococcus and/or influenza antibody titres in vaccinated patients during 24 months of treatment	From baseline to month 24
Primary	Proportion without new MRI activity	Proportion of patients with no new or enlarging T2-weighted brain MRI lesions	From month 6 (re-baseline) to month 24
Secondary	Proportion of patients with 6-months confirmed disability progression (6M-CDP)	Proportion of patients with 6-months confirmed disability progression (6M-CDP) as measured by the Expanded disability status scale (EDSS) (Kurtzke 1983) from baseline to month 24. CDP-EDSS defined as an increase of one point in the EDSS score confirmed after 6 months, with an absence of relapse at the time of assessment.	From baseline to month 24
Secondary	Proportion of patients with 6-months confirmed disability improvement (6M-CDI)	Proportion of patients with 6-months confirmed disability improvement (6M-CDI) as measured by the Expanded disability status scale (EDSS) (Kurtzke 1983) from baseline to month 24. CDI-EDSS is defined as a decrease of one point in the EDSS score, confirmed after 6 months, with an absence of relapse at the time of assessment.	From baseline to month 24
Secondary	Annual relapse rate	The annual relapse rate from baseline to month 24	From baseline to month 24
Secondary	Proportion of patients without relapses	Proportion of patients without relapses from baseline to month 24	From baseline to month 24
Secondary	Proportion of patients with 6M-CDP in T25FW	Proportion of patients with 6M-CDP in T25FW (Cutter, Baier et al. 1999) from baseline to month 24. 6M-CDP in T25FW is defined as patients experiencing an increase of =20% from baseline which is confirmed after 6 months (Bosma, Kragt et al. 2010, Motl, Cohen et al. 2017).	From baseline to month 24
Secondary	Proportion of patients with 6M-CDP in 9-HPT	Proportion of patients with 6M-CDP in 9-HPT (Cutter, Baier et al. 1999) 8.2.6) from baseline to month 24. 6M-CDP in 9HPT is defined as patients experiencing an increase of =20% from baseline which is confirmed after 6 months (Bosma, Kragt et al. 2010, Feys, Lamers et al. 2017).	From baseline to month 24
Secondary	Proportion of patients with 6M-CDP in SDMT	Proportion of patients with 6M-CDP in SDMT from baseline to month 24. SDMT is defined as patients experiencing a reduction of 15% from baseline which is confirmed after 6 months (Strober, DeLuca et al. 2019, Marstrand, Osterberg et al. 2020)	From baseline to month 24
Secondary	Proportion of patients with no new or enlarging T2-weighted brain MRI lesions	Proportion of patients with no new or enlarging T2-weighted brain MRI lesions from baseline to month 6, and from baseline to month 24	From baseline to month 6, and from baseline to month 24
Secondary	Proportion of patients without new gadolinium enhancing T1-weighted brain MRI lesions	Proportion of patients without new gadolinium enhancing T1-weighted brain MRI lesions at month 6, month 12 and month 24	At month 6, month 12 and month 24
Secondary	Change in brain volumes	Change in brain volumes from baseline to month 24 and from month 6 to month 24	From baseline to month 24 and from month 6 to month 24
Secondary	Frequency of SAE/SAR and AESI during 24 months of treatment	Overall safety during 24 months of treatment	From baseline to month 24
Secondary	The frequency of immediate and delayed infusion reactions	The frequency of immediate and delayed infusion reactions during 24 months of treatment	From baseline to month 24
Secondary	Frequency of infections	The frequency of infections during 24 months of treatment	From baseline to month 24
Secondary	The frequency any malignancies	The frequency any malignancies during 24 months of treatment	From baseline to month 24
Secondary	Change in the quality of life (MSIS-29)	The Multiple Sclerosis Impact Scale (MSIS-29) is a 29-item self-report measure comprising 20 items associated with a physical scale and 9 items associated with a psychological scale, also translated and validated in Norwegian.; Patients are asked about the impact of MS on day-to-day life in the last 2 weeks. All items have 5 response options from 1 (not at all) to 5 (extremely). Each of the 2 scales are scored by adding up the responses across items, then converting to a 0 to 100 scale, where 100 indicates greater impact of disease on daily function (worse health).	From baseline to month 24
Secondary	Change in Health related Anxiety and Depression as measured by HADS	The Hospital Anxiety and Depression Scale (HADS) is a questionnaire developed to screen anxiety and depression among patients in hospital settings. It consists of two subscales, one measuring anxiety, with seven items, and another measuring depression, with seven items. The two subscales are scored separately. The scale has been validated for use among MS patients as a screening instrument for symptoms of psychological distress. Higher scores indicate higher levels of anxiety and depression.	From baseline to month 24
Secondary	Change in the fatigue (FSMC)	The Fatigue scale for motor and cognitive functions (FSMC) is a method for evaluating fatigue in multiple sclerosis and other neurological conditions. The FSMC was developed and validated on a large sample of MS patients and healthy controls and includes subscales for both physical (motor) and mental (cognitive) aspects of fatigue. It was tested against 2 other validated fatigue scales (Fatigue Severity Scale and Modified Fatigue Impact Scale), and found to have better sensitivity and specificity than either of these instruments (Penner, Raselli et al. 2009). The FSMC has also undergone linguistic validation in over 20 languages, including Norwegian.	From baseline to month 24
Secondary	Change in EQ-5D score	The EQ-5D-5L self-report questionnaire essentially consists of 2 pages comprising: The descriptive system (five dimensions of health; namely mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension comprises three levels (no problems, some/moderate problems/extreme problems).; The EQ-VAS (visual analogue scale) which records the patient's self-rated health status on a vertical graduated (0 - 100) VAS.	From baseline to month 24
Secondary	Change in employment status	Patients will be asked about employment status at each visit (according to the following criteria: employed, unemployed, part-time employed, disability pension).	From baseline to month 24
Secondary	The frequency of anti-drug-antibodies	The frequency of anti-drug-antibodies during 24 months of treatment	From baseline to month 24

External Links

•   Neuro-sysmed overview